100% Locally Owned, Independent and Free

100% Locally Owned, Independent and Free

Trial could be significant step forward in pursuit of new treatment for autoimmune disease

Do you have a news tip? Click here to send to our news team.

Development with 152 units proposed for CBD

A five-storey development with 152 one-bedroom ‘rooming’ units has been proposed for the heart of Nambour. The proposal covers seven lots totalling 2792sqm on the More

Couple appeals refusal of beachfront rebuild plans

An appeal has been launched in the Planning and Environment Court after a council rejected a couple’s bid to redevelop their beachfront property. Linda and More

WATCH: Arrest made after spikes used on alleged stolen truck

A man has been arrested after an alleged stolen truck was tracked more than 200km, with police deploying tyre spikes on the highway on More

Sunshine Coast back on top for regional migration

The Sunshine Coast has reclaimed its position as Australia’s number one regional migration destination for people moving from capital cities. The rapidly growing beach haven More

Ashley Robinson: Foiled again on the home front

I have written about retirement before and the implications it may have for me spending more time at home with Old Mate. There have been More

Property price surge drives buyers to the Coast

A leading property developer is urging buyers to invest at the southern end of the Sunshine Coast, with record Brisbane housing prices having a More

A potential new treatment for rheumatoid arthritis will be tested on the Sunshine Coast.

The University of the Sunshine Coast Clinical Trials and Servatus Biopharmaceuticals Ltd are collaborating to trial a live biotherapeutic product, which is a field of medical therapy that is advancing globally.

Principal investigator Dr Peter de Wet said rheumatoid arthritis was an autoimmune disease that occurred when the immune system mistakenly attacked the body’s tissues, affecting the joints’ lining and causing joint pain and stiffness.

“Rheumatoid arthritis can be a debilitating condition that can impact many aspects of daily living,” he said via a UniSC media release.

“We are interested to learn about the role of the gut microbiome in treating symptoms of this condition.

“And while there are various strategies to improve joint mobility and muscle strength and reduce inflammation, some treatments are ineffective or have unwanted side effects, highlighting the need for new medicines to address the condition.”

He said the trial, to be held at UniSC’s newest clinic at Birtinya, represented a significant step forward in the pursuit of a new treatment.

Clinical Trials coordinator Jacinta Trevaskis.

Dr Samantha Coulson, head of clinical research at Servatus, said the live biotherapeutic product was an exciting and promising field of medical therapies that was advancing quickly on a global scale.

Servatus has isolated select microbial species, and pre-clinical investigations suggest the potential medication may be effective in treating autoimmune and inflammatory conditions.

“The gut microbiome plays such a vital role in many diseased states including rheumatoid arthritis, as the gut bacteria and immune system have a bidirectional influence on each other,” Dr Coulson said.

By using well-defined bacterial strains, we hope to regulate the hyperactive immune response seen in rheumatoid arthritis with significantly less side effects as with many of the current drugs in the market.

The product that could make a difference.

The team is seeking participants aged between 18 and 80 with confirmed rheumatoid arthritis and who are experiencing daily joint pain and stiffness.

Participants will need to commit to up to six visits at the Birtinya clinic over about four months and they will be reimbursed for their time on the trial.

Those interested in volunteering can find more information at UniSC Clinical Trials.

Local journalists supporting local people. Help keep independent and fair Sunshine Coast news coming by subscribing to our FREE daily news feed. All it requires is your name and email at the bottom of this article.

Subscribe to SCN’s free daily news email

This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.
[scn_go_back_button] Return Home
Share